미국의 네뷸라이저 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 부문 예측(2024-2030년)

U.S. Nebulizer Market Growth & Trends:

The U.S. nebulizer market size is anticipated to reach USD 412.6 million by 2030, according to a new report by Grand View Research, Inc., expanding at a 5.4% CAGR during the forecast period. Rising incidence of chronic respiratory diseases in U.S., increasing demand for home healthcare devices, and growing geriatric population are among the key factors driving market growth.

Rising incidence of chronic respiratory diseases is a crucial driver for market growth. According to statistics published by the Centers for Disease Control and Prevention (CDC), approximately 18.4 million adults in U.S. suffer from asthma. Chronic obstructive pulmonary disease (COPD) was estimated to be the third leading cause of death in the country in 2014, according to the CDC, with around 15.7 million Americans diagnosed with the condition that year. Factors such as overconsumption of tobacco and alcohol, unhealthy diet, lack of physical activity, and alarming rates of obesity are also likely to lead to an increase in incidence of respiratory disorders in U.S., contributing to the growth of the nebulizer market over the forecast period.

Home healthcare devices have been gaining popularity and market share in recent years. Growing geriatric population in U.S., high incidence of target diseases, and rising need to curb healthcare expenditure are expected to be some of the high-impact rendering drivers for home healthcare devices. Home healthcare is a cost-effective alternative to expensive hospital stays. Easy availability of compact nebulizers ideal for home use and technological innovations in nebulizers to reduce noise and improve functionality are increasing their adoption in home healthcare. Moreover, third-party payers, such as insurance companies, favor such devices as they aim to reduce costs while providing quality healthcare services. Such factors are also expected to contribute to market growth.

U.S. Nebulizer Market Report Highlights:

• Mesh is expected to register the fastest CAGR of 5.8% over the forecast period owing to its advanced technology that provides fast and highly effective drug delivery when compared to that of a usual nebulizer.
• The asthma segment dominated the market in 2023 and accounted for a market share of 40.0% driven by the high prevalence of asthma, which requires regular and effective administration of drugs for disease management.
• The hospitals and clinics segment dominated the market in 2023. The hospitals and clinics provide a controlled environment with physicians trained to administer nebulized drugs, especially for critical cases or patients who require intensive care.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Nebulizer Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. U.S. Nebulizer Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Nebulizer Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Nebulizer Market: Type Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Jet
  • 4.3.1. Jet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Mesh
  • 4.4.1. Mesh Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Ultrasonic
  • 4.5.1. Ultrasonic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Nebulizer Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Nebulizer Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. COPD
  • 5.3.1. COPD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Asthma
  • 5.4.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Nebulizer Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Nebulizer Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Hospitals and Clinics
  • 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Emergency Centers
  • 6.4.1. Emergency Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. OMRON Healthcare, Inc.
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. GE Healthcare
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Koninklijke Philips N.V.
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. Allied Healthcare
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Vectura Group Plc.
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. PARI Respiratory Equipment, Inc.
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Aerogen
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. DeVilbiss Healthcare LLC
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. Briggs Healthcare
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. Beurer GmBH
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/ Strategic Initiatives